| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 435328000 |
Immunoglobulin or antibody is chimeric, mutated, or a recombined hybrid (e.g., bifunctional, bispecific, rodent-human chimeric, single chain, rFv, immunoglobuin fusion protein, etc.)
| 58 |
| 435332000 |
Immunoglobulin or antibody binds a microorganism or normal or mutant component or product thereof (e.g., animal cell, cell surface antigen, secretory product, etc.)
| 39 |
| 435331000 |
Immunoglobulin or antibody binds a specifically identified amino acid sequence
| 22 |
| 435330000 |
Immunoglobulin or antibody binds an expression product of a cancer related gene or fragment thereof (e.g., oncogene, proto-oncogene, etc.) | 2 |
| 20090162931 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS - The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids. | 06-25-2009 |
| 20090170191 | 84P2A9: A PROSTATE AND TESTIS SPECIFIC PROTEIN HIGHLY EXPRESSED IN PROSTATE CANCER - A novel gene (designated 84P2A9) and its encoded protein is described. While 84P2A9 exhibits prostate and testis specific expression in normal adult tissue, it is aberrantly expressed multiple cancers including prostate, testis, kidney, brain, bone, skin, ovarian, breast, pancreas, colon, lymphocytic and lung cancers. Consequently, 84P2A9 provides a diagnostic and/or therapeutic target for cancers, and the 84P2A9 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response. | 07-02-2009 |
| 435327000 |
Immunoglobulin or antibody is anti-idiotypic | 1 |
| 20140134719 | RECOMBINANT CELL SURFACE CAPTURE PROTEINS - Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and/or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT). | 05-15-2014 |
| 435345000 |
Immunoglobulin or antibody binds a drug, hapten, hapten-carrier complex, or specifically identified chemical structure (e.g., theophylline, digoxin, etc.) | 1 |
| 20090221066 | Anti-Methylated Dna Antibody and Method for Production Thereof - The present invention provides a method of preparing an anti-methylated DNA antibody, comprising a step of administering to an animal an oligodeoxyribonucleotide containing a methylated cytosine(s) and an oligodeoxyribonucleotide containing no methylated cytosine. The antibody prepared by this method is capable of detecting a DNA containing a methylated cytosine(s) in a state close to the state of a biological component. | 09-03-2009 |
| Entries |
| Document | Title | Date |
|---|
| 20080261301 | Antibody Composition-Producing Cell - The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof. | 10-23-2008 |
| 20090239296 | Compositions and Methods for Modifying Cell Surface Glycans - Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein. | 09-24-2009 |
| 20090291493 | HUMAN IMMUNODEFICIENCY VIRUS-NEUTRALIZING ANTIBODIES WITH IMPROVED BREADTH AND POTENCY - The present invention provides an antibody to human immunodeficiency virus (HIV) envelope glycoprotein that can recognize one or more strains of HIV, wherein the epitope of HIV recognized by the antibody is inducible, and wherein the antibody binding to the epitope is enhanced by the presence of CD4 and the HIV co-receptor, and related fusion proteins, conjugates, nucleic acids, vectors, host cells, compositions and methods of use to inhibit an infection of a human at risk of becoming infected with HIV, to reduce the severity of an infection of a human infected with HIV, and to treat an infection of a human with HIV. | 11-26-2009 |
| 20090325287 | Methods for Obtaining High Viable Cell Density in Mammalian Cell Culture - Methods for increasing viability in fed batch eukaryotic cell culture are disclosed. | 12-31-2009 |
| 20100021995 | BIOLOGICAL PRODUCTS - There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22. | 01-28-2010 |
| 20100021996 | Genetically Altered Anti-body Producing Cell Lines With Improved Antibody Characteristics - Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. Cells may be selected for expression of activation-induced cytidine deaminase (AID), stimulated to produce AID, or manipulated to express AID for further enhancement of hypermutability. These methods are useful for generating genetic diversity within immunoglobulin genes directed against an antigen of interest to produce altered antibodies with enhanced biochemical activity. Moreover, these methods are useful for generating antibody-producing cells with increased level of antibody production. | 01-28-2010 |
| 20100075413 | IMPROVED PROCESS FOR THE CULTURING OF CELLS - The invention relates to a process for the culturing of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the cells, the biological substance and cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture. | 03-25-2010 |
| 20100136683 | METHODS FOR ISOLATING CELLS BASED ON PRODUCT SECRETION - The invention provides methods for purifying one or more cells based on the level of one or more products secreted by the cells. In one embodiment, the method involves (a) contacting a plurality of cells immobilized in proximity to a capture matrix, the capture matrix capable of localizing a product secreted by one or more of the cells, with an agent that selectively binds to the product, the agent capable of generating a signal detectable as a property of light; (b) illuminating a population of the cells, the population contained in a frame; (c) detecting two or more properties of light directed from the frame, wherein a first property of light identifies substantially all cells of the population, and the second property of light identifies product localized to the capture matrix; (d) locating (i) substantially all cells of the population with reference to the detected first property of light, and (ii) one or more selected cells with reference to the detected second property of light, and (e) irradiating the non-selected cells, wherein each non-selected cell receives a substantially lethal dose of radiation, whereby one or more selected cells having a desired product secretion profile are purified. | 06-03-2010 |
| 20100203630 | IN VITRO HUMAN B LYMPHOPOIESIS CULTURE SYSTEM - The present disclosure relates to systems, methods and compositions for the generation of antibody-producing B cells in vitro. Some embodiments are related to an in vitro system for generating antibody-producing B cells from hematopoietic stem/progenitor cells (HSPCs). | 08-12-2010 |
| 20100203631 | ANTIBODIES TO ALPHA-SYNUCLEIN - The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes. | 08-12-2010 |
| 20100311160 | Cultures of E1-immortalized cells and processes for culturing the same to increase product yields therefrom - Provided are processes for culturing cells derived from embryonic retinoblast cells immortalized by adenovirus E | 12-09-2010 |
| 20110003382 | USE OF CORTICOSTERONE FOR INCREASING EGG ANTIBODY - Methods for increasing antigen-specific egg yolk antibody titer and eggs having increased antigen-specific egg yolk antibody titer are disclosed. More specifically, the method for increasing antibody titer may include the steps of: administering to an egg-laying animal a corticosteroid; and then, exposing the animal to an immunogenic dose of the antigen. | 01-06-2011 |
| 20110027878 | RANDOM HOMOZYGOUS GENE PERTURBATION TO ENHANCE ANTIBODY PRODUCTION - The invention reflects enhanced antibody expression of an antibody of interest by cell lines transformed by random homozygous gene perturbation methods to either increase or decrease the expression pattern of a gene of the cell line other than the antibody of interest. The transformed cell line exhibits specific productivity rates, SPR, for the RHGP transformed cell liens of 1.5 or more, as compared with the antibody expressing cell line parents prior to transformation by RHGP. A knock out or anti-sense construct may be devised to reduce expression of the target gene, a promoter may be inserter to enhance expression of the target gene. The antibodies expressed by the transformed cell lines exhibit the binding properties of their parent cell lines prior to transformation with RHGP, and increase Total Volumetric Production of said antibody by said cells in a given volume. | 02-03-2011 |
| 20110076763 | NEOPLASM SPECIFIC ANTIBODIES AND USES THEREOF - The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms. | 03-31-2011 |
| 20110129916 | MONOCLONAL ANTIBODIES WITH SPECIFICITY FOR FETAL ERYTHROID CELLS - The present invention concerns a monoclonal antibody and corresponding hybridoma cells and antigens suitable for isolating fetal cells from maternal blood. The inventive monoclonal antibody reacts with a surface antigen present on fetal red blood cells including their nucleated precursor cells, but not with surface antigens on adult erythroid cell. | 06-02-2011 |
| 20110143432 | USE OF EXTRACT OF SELENIUM-ENRICHED YEAST (SE-YE) IN MAMMALIAN CELL CULTURE MEDIA FORMULATIONS - The invention relates to the use of extract of selenium-enriched yeast (Se-YE) as a supplement to the serum-free cell culture media formulations. The cell culture media comprising this supplement are particularly suitable for cultivating mammalian cells and for production of recombinant proteins and monoclonal antibodies. | 06-16-2011 |
| 20110275147 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 11-10-2011 |
| 20110287533 | NOVEL LOWERED AFFINITY ANTIBODIES AND USES THEREFOR - The present invention provides novel, rationally designed lowered affinity antibodies for use in various in vivo and in vitro applications. The antibodies of the present invention have variable domains that have been designed to reduce or eliminate the antigen binding activity of the parental antibody without altering the overall 3 dimensional antibody structure. Using the antibodies of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects. | 11-24-2011 |
| 20120252117 | OPTIMIZED MESSENGER RNA - The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons. | 10-04-2012 |
| 20120315697 | Cell Culture Media Containing Combinations of Proteins - The present invention relates to cell culture media containing combinations of proteins, as well as methods of making the cell culture media, and methods of using the cell culture media to improve growth characteristics of cultured cells. | 12-13-2012 |
| 20130071921 | ANTIBODIES SPECIFIC FOR DKK-1 AND THEIR USES - The present invention provides antibodies and fragments thereof that bind to Dkk-1 and, in particular, to humanized antibodies and fragments thereof that bind to Dkk-1 and, even more particularly to fully humanized antibodies and immunologically functional fragments that bind to Dkk-1. Also provided are antibodies and fragments thereof which compete with the binding of an anti-mouse Dkk-1 monoclonal antibody for binding to Dkk-1 | 03-21-2013 |
| 20140038284 | Mammalian Cell Lines for Increasing Longevity and Protein Yield from a Cell Culture - Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells. | 02-06-2014 |
| 20140141506 | Vectors, Host Cells, and Methods of Production and Uses - Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids. | 05-22-2014 |
| 20140170746 | METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELLS USING MICROVESICLES DERIVED FROM EMBRYONIC STEM CELLS - Provided is a method of dedifferentiating somatic cells using embryonic stem cell-derived microvesicles. Particularly, a method of preparing induced pluripotent stem cells by treating a composition including embryonic stem cell-derived microvesicles to the somatic cells. According to the method of preparing induced pluripotent stem cells, the dedifferentiation of the somatic cells may be efficiently performed without side effects using the embryonic stem cell-derived microvesicles, and moreover, the method is expected to be very useful in developing a cell therapy product having immunocompatibilities by individuals. | 06-19-2014 |
| 20140335609 | PROTEIN EXPRESSION FROM MULTIPLE NUCLEIC ACIDS - The current invention reports a method for the recombinant production of a secreted heterologous immunoglobulin in a CHO cell comprising the following steps: i) providing a CHO cell, which is adapted to growth in suspension culture, adapted to growth in serum-free medium, mycoplasma free, and virus free, ii) providing a vector comprising a prokaryotic origin of replication, a first nucleic acid conferring resistance to a prokaryotic selection agent, a second nucleic acid encoding the heavy chain of said heterologous immunoglobulin, a third nucleic acid encoding the light chain of said heterologous immunoglobulin, a fourth nucleic acid conferring resistance to a eukaryotic selection agent, iii) transfecting said CHO cell, wherein said transfecting comprises a) transfecting said CHO cell with said vector comprising a fourth nucleic acid conferring resistance to a first eukaryotic selection agent, b) selecting a CHO cell by growth in cultivation medium containing said first eukaryotic selection agent, c) transfecting said selected CHO cell with said vector comprising a fourth nucleic acid conferring resistance to a second eukaryotic selection agent different to said first eukaryotic selection agent, d) selecting a CHO cell by selected growth in cultivation medium containing said first and said second eukaryotic selection agent, iv) cultivating said transfected CHO cell in a medium in the presence of said first and second eukaryotic selection agent, under conditions suitable for the expression of said second, and third nucleic acid, and v) recovering said secreted heterologous immunoglobulin from the cultivation medium. | 11-13-2014 |
| 20140349393 | Fusion Partner for Production of Monoclonal Rabbit Antibodies - The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications. | 11-27-2014 |
| 20140349394 | TARGETED INTEGRATION INTO THE PPP1R12C LOCUS - Disclosed herein are methods and compositions for targeted integration of an exogenous sequence into the human PPP1R12C locus, for example, for expression of a polypeptide of interest. | 11-27-2014 |
| 20150147805 | Vectors, Host Cells, and Methods of Production and Uses - Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids. | 05-28-2015 |
| 20150299655 | METHOD FOR OBTAINING ANTIGEN-SPECIFIC HUMAN ANTIBODIES BY IN VITRO IMMUNISATION - A method for the in vitro immunisation of human B lymphocytes, comprising culturing a total mononuclear cell population of human peripheral blood in the presence of an antigenic composition comprising at least one antigen covalently bonded to both: (i) a Tat protein or a Tat fragment capable of oligomerisation and (ii) a ligand of a surface molecule specific to the antigen presenting cells; a method for producing antigen-specific human antibodies derived from said in vitro immunisation method. | 10-22-2015 |
| 20160060598 | MEANS AND METHODS FOR INFLUENCING THE STABILITY OF ANTIBODY PRODUCING CELLS - The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines. | 03-03-2016 |
